Last Updated : March 6, 2025
Details
Generic Name:
venetoclax
Project Status:
Active
Therapeutic Area:
Mantle cell lymphoma (MCL)
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0402-00
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Venclexta in combination with ibrutinib, is indicated for the treatment of adult patients with MCL who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Venclexta, in combination with ibrutinib, is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Jan-25 |
|---|---|
| Call for patient/clinician input closed | 03-Mar-25 |
| Submission received | 20-Feb-25 |
| Submission accepted | 06-Mar-25 |
| Review initiated | 07-Mar-25 |
| Draft CADTH review report(s) provided to sponsor for comment | 26-May-25 |
| Deadline for sponsors comments | 04-Jun-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 26-Jun-25 |
| Expert committee meeting (initial) | 09-Jul-25 |
| Draft recommendation issued to sponsor | - |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | - |
Last Updated : March 6, 2025